

# APOLLO HOSPITALS ENTERPRISE LIMITED



December 24, 2025 CIN : L85110TN1979PLC008035

**Bombay Stock Exchange Ltd (BSE)**

Phiroze Jheejheebhoy Towers,  
Dalal Street,  
Mumbai – 400 001.  
Scrip Code – 508869  
ISIN INE437A01024

**National Stock Exchange of India Limited (NSE)**

Exchange Plaza, 5th Floor,  
Plot No. C/1, 'G' Block  
Bandra – Kurla Complex  
Bandra (E)  
Mumbai – 400 051.  
Scrip Code – APOLLOHOSP  
ISIN INE437A01024

**Subject:** Receipt of observation letter from the BSE Limited (“BSE”) in relation to the proposed composite scheme of arrangement amongst Apollo Hospitals Enterprise Limited (“Company”), Apollo Healthco Limited (“Transferor Company 1”), Keimed Private Limited (“Transferor Company 2”) and Apollo Healthtech Limited (“Resultant Company”) and their respective shareholders and creditors (“Scheme”), under Sections 230 to 232, and other applicable provisions of the Companies Act, 2013 read with the rules made thereunder.

**Ref:** Disclosure under Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”).

Dear Sir / Ma’am,

This is with reference to our letter dated June 30, 2025, informing about the decision of the board of directors of the Company approving the Scheme involving, *inter alia*, the demerger of the Identified Business Undertaking (as defined in the Scheme) of the Company into Resultant Company, the amalgamation of Transferor Company 1 with and into Resultant Company, the amalgamation of Transferor Company 2 with and into Resultant Company, and the consequent listing of equity shares of Resultant Company on NSE and BSE and admission to trading, subject to receipt of applicable approvals from regulatory and statutory authorities.

The Scheme remains subject to the receipt of requisite statutory and regulatory approvals as may be required, the approval of the shareholders and creditors of the company(ies) involved in the Scheme, as may be applicable, and other terms and conditions as set out in the Scheme.


On September 24, 2025, we had intimated of the receipt of approval of the Competition Commission of India for the transactions contemplated under the Scheme. In furtherance to that, we would like to inform you that the Company has received the observation letter from BSE on December 24, 2025, in relation to the Scheme, under Regulation 37 of the Listing Regulations. A copy of the said observation letter dated December 24, 2025, is enclosed herewith. The said observation letter is also made available on the website of the Company at [www.apollohospitals.com](http://www.apollohospitals.com)

We request you to take the aforesaid on record, and to treat the same as compliance with the applicable provisions of the Listing Regulations.

Thanking you,

Yours sincerely,

For Apollo Hospitals Enterprise Limited

  
S.M. Krishnan  
Sr. Vice President – Finance  
& Company Secretary

IS/ISO 9001 : 2000

**Regd. Office :**

19, Bishop Gardens,  
Raja Annamalaipuram,  
Chennai - 600 028.

**General Office :**

“Ali Towers” III Floor,  
#55, Greams Road,  
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681

Telefax : 044 - 2829 0956

Email : [investor.relations@apollohospitals.com](mailto:investor.relations@apollohospitals.com)

Website : [www.apollohospitals.com](http://www.apollohospitals.com)

Ref. no.: DCS/AMAL/TS/R37/3972/2025-26

December 24, 2025

To,  
The Company Secretary,  
**Apollo Hospitals Enterprise Limited**  
No. 19, Bishop Gardens, Raja Annamalaipuram,  
Chennai, Tamil Nadu - 600 028.


Dear Sir/Madam,

**Sub: Scheme of Arrangement involving the demerger of Apollo Hospitals Enterprise Limited into Apollo Healthtech Limited, the amalgamation of Apollo Healthco Limited and M/s. Keimed Private Limited with and into Apollo Healthtech Limited into Apollo Healthtech Limited and their respective shareholders and creditors**

We refer to your application for Scheme of Arrangement involving the demerger of the Identified Business Undertaking of Apollo Hospitals Enterprise Limited ("AHEL"/"Demerged Company") into Apollo Healthtech Limited ("AHTL"/"Resultant Company"), the amalgamation of Apollo Healthco Limited ("AHL"/"Transferor Company 1") into Resultant Company, the amalgamation of M/s. Keimed Private Limited ("KPL"/"Transferor Company 2") into Resultant Company and their respective shareholders and creditors under Sections 230 to 232 read with Section 66 and other applicable provisions of the Companies Act, 2013, and rules made thereunder filed with the Exchange under Regulation 37 and Regulation 94(2) of SEBI LODR Regulations, 2015, read with SEBI Master Circular no. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023.

In this regard, SEBI vide its letter dated December 22, 2025, has *inter-alia*, given the following comment(s) on the said scheme of Arrangement:

1. "The Entity shall ensure to disclose all details of ongoing adjudication & recovery proceedings, prosecution initiated, and all other enforcement action taken, if any, against the listed entity, its promoters and directors, before Hon'ble NCLT and shareholders, while seeking approval of the scheme."
2. "The Entity shall ensure that additional information, if any, submitted by the listed entity after filing the scheme with the Stock Exchange, from the date of receipt of this letter, is displayed on the websites of the listed Company and the Stock Exchanges."

TS 


3. "The Entity shall ensure compliance with the SEBI circulars issued from time to time. The entities involved in the Scheme shall duly comply with various provisions of the Master Circular and ensure that all the liabilities of Transferor Companies are transferred to the Resultant Company."
4. "The Entity is advised that the information pertaining to all the Unlisted Companies, if any, involved in the scheme shall be included in the format specified for abridged prospectus as provided in Part E of Schedule VI of the ICDR Regulations, 2018, in the explanatory statement or notice or proposal accompanying resolution to be passed, which is sent to the shareholders for seeking approval."
5. "The Entity shall ensure that the financials in the scheme including financials considered for valuation report are not for period more than 6 months old."
6. "The entity is advised listed entity that the details of the proposed scheme under consideration as provided by the listed entity to the Stock Exchange shall be prominently disclosed in the notice sent to the Shareholders."
7. "The entity is advised that the proposed equity shares, if any, to be issued in terms of the "Scheme" shall mandatorily be in demat form only."
8. "The entity is advised that the "Scheme" shall be acted upon subject to the listed entity complying with the relevant clauses mentioned in the scheme document."
9. "No changes to the draft scheme except those mandated by the regulators/authorities/tribunals shall be made without specific written consent of SEBI."
10. "The entity is advised that the observations of SEBI/Stock exchanges shall be incorporated in the petition to be filed before NCLT and the company is obliged to bring the observations to the notice of NCLT."
11. "The entity is advised to comply with the all applicable provisions of the Companies Act, 2013, rules and regulations issued thereunder including obtaining the consent from the creditors for the proposed scheme."
12. "The entity is advised to ensure that the following additional disclosure to the public shareholders as a part of explanatory statement or notice or proposal accompanying resolution to be passed to be forwarded by the company to the shareholders while

Ts R

seeking approval u/s 230 to 232 of the Companies Act, 2013, to enable them to take an informed decision:

- a. Details of assets, liabilities, net worth and revenue of the companies involved, pre and post scheme.
  - b. Impact of scheme on revenue generating capacity of listed entity.
  - c. Need and Rationale of the scheme, Synergies of business of the companies involved in the scheme, Impact of the scheme on the shareholders and cost benefit analysis of the scheme.
  - d. Value of assets and liabilities of Demerged Company that are being transferred to Resultant Company.
  - e. Details/facts about the basis of valuation including projections considered for valuation of transferor and transferee companies along with justification for growth rate considered for valuation.
  - f. Details/facts about the basis of valuation pertaining to the demerger of identified Business Undertaking of the Demerged Company into the Resulting Company along with the justification for the methodology adopted.
  - g. Latest financials of demerged, transferor and resulting companies should be updated on the Website and same also to be disclosed in the explanatory statement.
  - h. Revised shareholding pattern of demerged, transferor and resulting companies Pre and Post-Merger.
  - i. Pre and Post scheme shareholding of demerged, transferor and resulting companies as on the date of notice of Shareholders meeting along with rationale for changes, if any, occurred between filing of Draft Scheme to Notice to shareholders.
  - j. Disclose all pending actions against the entities involved in the scheme its promoters/directors/KMPs and possible impact of the same on the Transferee Company to the shareholders.
  - k. Stock Exchange shall ensure that applicable additional information, if any to be submitted to SEBI along with draft scheme of arrangement as advised by email dated December 24, 2025, shall form part of disclosures to the shareholders.
13. "It is to be noted that the petitions are filed by the company before NCLT after processing and communication of comments/observations on draft scheme by SEBI/stock exchange. Hence, the company is not required to send notice for representation as mandated under section 230(5) of Companies Act, 2013 to SEBI again for its comments/observations/representations."

Accordingly, based on aforesaid comments offered by SEBI, the Company is hereby advised:

T3 

- To provide additional information, if any, (as stated above) along with various documents to the Exchange for further dissemination on Exchange website.
- To ensure that additional information, if any, (as stated aforesaid) along with various documents are disseminated on their (company) website.
- To duly comply with various provisions of the circulars.

In light of the above, we hereby advise that we have no adverse observations with limited reference to those matters having a bearing on listing/de-listing/continuous listing requirements within the provisions of Listing Agreement, so as to enable the company to file the scheme with Hon'ble NCLT.

Please note that the submission of documents/information, in accordance with the circular to SEBI/Exchange should not in any way be deemed or construed that the same has been cleared or approved by SEBI/Exchange. SEBI/Exchange does not take any responsibility either for the financial soundness of any scheme or for the correctness of the statements made or opinions expressed in the document submitted.

Further, where applicable in the explanatory statement of the notice to be sent by the Company to the shareholders, while seeking approval of the scheme, it shall disclose Information about unlisted companies involved in the format prescribed for abridged prospectus as specified in the SEBI Master Circular dated June 20, 2023.

However, the listing of equity shares of Apollo Healthtech Limited shall be subject to SEBI granting relaxation under Rule 19(2)(b) of the Securities Contract (Regulation) Rules, 1957, and compliance with the requirements of SEBI circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023. Further, Apollo Healthtech Limited shall comply with SEBI Act, Rules, Regulations, directions of the SEBI and any other statutory authority and Rules, Byelaws, and Regulations of the Exchange. The Companies shall fulfil the Exchange's criteria for listing the securities of such Companies and also comply with other applicable statutory requirements. However, the listing of shares of Apollo Healthtech Limited is at the discretion of the Exchange. In addition to the above, the listing of Apollo Healthtech Limited pursuant to the Scheme of Arrangement shall be subject to SEBI approval and the Company satisfying the following conditions:

1. To submit the Information Memorandum containing all the information about Apollo Healthtech Limited in line with the disclosure requirements applicable for public issues with BSE, for making the same available to the public through the website of the Exchange. Further, the Companies are also advised to make the same available to the public through its website.

TSB

2. To publish an advertisement in the newspapers containing all details of Apollo Healthtech Limited in line with the details required as per the aforesaid SEBI circular no. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023. The advertisement should draw a specific reference to the aforesaid Information Memorandum available on the website of the company as well as BSE.
3. To disclose all the material information about Apollo Healthtech Limited on a continuous basis so as to make the same public, in addition to the requirements if any, specified in Listing Agreement for disclosures about the subsidiaries.
4. The following provisions shall be incorporated in the scheme:
  - "The shares allotted pursuant to the Scheme shall remain frozen in the depository system till listing / trading permission is given by the designated stock exchange."
  - "There shall be no change in the shareholding pattern of Apollo Healthtech Limited between the record date and the listing which may affect the status of this approval."

Further you are also advised to bring the contents of this letter to the notice of your shareholders, all relevant authorities as deemed fit, and also in your application for approval of the scheme of Arrangement.

Kindly note that as required under Regulation 37(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the validity of this Observation Letter shall be Six Months from the date of this Letter, within which the scheme shall be submitted to the NCLT.

The Exchange reserves its right to withdraw its 'No adverse observation' at any stage if the information submitted to the Exchange is found to be incomplete/incorrect/misleading/false or for any contravention of Rules, Bye-laws and Regulations of the Exchange, Listing Agreement, Guidelines/Regulations issued by statutory authorities.

Please note that, the aforesaid observations do not preclude the Company from complying with any other requirements.


Further, it may be noted that with reference to Section 230 (5) of the Companies Act, 2013, (Act) read with Rule 8 of Companies (Compromises, Arrangements and Amalgamations) Rules, 2016, (Company Rules) and Section 66 of the Act read with Rule 3 of the Company Rules wherein pursuant to an Order passed by the Hon'ble National Company Law Tribunal, a Notice of the proposed scheme of compromise or arrangement filed under sections 230-232 or Section 66 of the Act the case may be is required to be served upon the Exchange seeking representations or objections if any.

TSR

In this regard, with a view to have a better transparency in processing the aforesaid notices served upon the Exchange, the Exchange has already introduced an online system of serving such Notice along with the relevant documents of the proposed schemes through the BSE Listing Centre.

Any service of notice under Section 230 (5) or Section 66 of the Act seeking Exchange's representations or objections if any, would be accepted and processed through the Listing Centre only and no physical filings would be accepted. You may please refer to circular dated February 26, 2019, issued to the company.

Yours faithfully,



Kinnar Mehta

Assistant Vice President



Toshika Sharma

Deputy Manager